What makes the SU2C research model so different for cancer research?
Cantley: This new approach to funding as well as the researchers’ collaborative approach [means] there is sufficient money to put together teams across institutions and still have enough so people can actually reach their goals. We can bring in people who have very strong expertise in different fields to share the money and their expertise. Dr. Jones: In addition, it allows people to draw up collaborative arrangements with their colleagues and competitors much more quickly than is usually the case. With this initiative, there was a clear urgency to get the right people together as quickly as possible. Dr. Slamon: We all believe in this model, and I agree that it is unique in demanding a multi-institutional approach of experts. Also, the team leaders will be interacting among teams where there is obvious overlap, sharing information across teams, not just within teams. Q: Dr. Cantley, your area of research is the PI3K “pathway,” a process that leads to cancerous cells growing and surviv
